BioWorld

Jan. 7, 2002

Abgenix Drops ABX-IL8 For RA Following Phase II Trial Results

Abgenix Inc. s stock took a small hit Friday following the disclosure that a Phase IIa study of its rheumatoid arthritis candidate failed to meet its endpoints. Read More

Aurora, Allergan Expand Work To Include GPCR Screening

Industry, Academia Knock Out Immune Rejection Gene From Porcine Xenotransplant Grafts

Acadia Partners With Amgen To Discover Small-Molecule Drugs

Other News To Note

3-D Pharma, J&J Collaborate On Small-Molecule Drug Discovery

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 4, 2025.

Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

BioWorld

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...

Pharma execs speak out: UK pricing rebates scare investors

BioWorld

The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...

ASCO 2025: Verastem has positive cancer data but stock sags

BioWorld

New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...